{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:43:31Z","timestamp":1755225811092,"version":"3.43.0"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Science and Technology Development Fund, Macau SAR","award":["0005\/2024\/AKP"],"award-info":[{"award-number":["0005\/2024\/AKP"]}]},{"name":"the Science and Technology Development Fund, Macau SAR","award":["005\/2023\/SKL"],"award-info":[{"award-number":["005\/2023\/SKL"]}]},{"name":"the Science and Technology Development Fund, Macau SAR","award":["0075\/2022\/A"],"award-info":[{"award-number":["0075\/2022\/A"]}]},{"name":"the Science and Technology Development Fund, Macau SAR","award":["028\/2022\/ITP"],"award-info":[{"award-number":["028\/2022\/ITP"]}]},{"name":"Zhuhai Science and Technology Plan Project in the Social Development Field","award":["2220004000117"],"award-info":[{"award-number":["2220004000117"]}]},{"name":"the University of Macau","award":["MYRG-GRG2023-00082-ICMS-UMDF"],"award-info":[{"award-number":["MYRG-GRG2023-00082-ICMS-UMDF"]}]},{"name":"the University of Macau","award":["MYRG-GRG2024-00150-ICMS-UMDF"],"award-info":[{"award-number":["MYRG-GRG2024-00150-ICMS-UMDF"]}]},{"name":"the University of Macau","award":["CPG2025-00030-ICMS"],"award-info":[{"award-number":["CPG2025-00030-ICMS"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Gout, caused by hyperuricemia, has a detrimental impact on patients\u2019quality of life. The urate transporter 1 (URAT1) stands out as a key therapeutic target. However, its clinical development remains uncertain. This study aims to explore the landscape of URAT1 inhibitors by combining global patent analytics with computational drug design. We utilized the Derwent Innovation platform to analyze patents (from 2005 to 2024). Molecular docking was performed on 73.96% of novel compounds using AutoDock Vina. Additionally, scaffold diversity was analyzed using the Bemis-Murcko (BM) scaffold approach. A total of 2,195 entries were screened and eventually narrowed down to 1,056 high-value entries. The global research on URAT1 inhibitors is highly active, with China, the US, Japan, and Europe leading. Most patents are new compounds, indicating significant potential for novel drug development. Molecular docking showed ideal binding affinities for most compounds. The top five BM scaffolds were identified and compared with marketed drugs. This study highlights the potential for developing new URAT1 inhibitors. The identified compounds and scaffolds offer promising starting points for further drug development. Future work should focus on experimental validation and exploring clinical potential.<\/jats:p>","DOI":"10.1371\/journal.pone.0328559","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:50:14Z","timestamp":1755107414000},"page":"e0328559","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape"],"prefix":"10.1371","volume":"20","author":[{"given":"Jiaxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-0426","authenticated-orcid":true,"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huina","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"5","key":"pone.0328559.ref001","doi-asserted-by":"crossref","first-page":"102062","DOI":"10.1016\/j.jsps.2024.102062","article-title":"Unveiling potent Schiff base derivatives with selective xanthine oxidase inhibition: In silico and in vitro approach","volume":"32","author":"F Bellahcene","year":"2024","journal-title":"Saudi Pharm J"},{"issue":"12","key":"pone.0328559.ref002","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/13543776.2022.2165911","article-title":"Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)","volume":"32","author":"X Shi","year":"2022","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"pone.0328559.ref003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"L Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"pone.0328559.ref004","article-title":"Gout","volume":"388","author":"M Banerjee","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0328559.ref005","doi-asserted-by":"crossref","first-page":"19966","DOI":"10.1021\/acs.jmedchem.4c01260","article-title":"Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents","volume":"67","author":"Z Sun","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0328559.ref006","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"X-W Wu","year":"1992","journal-title":"J Mol Evol"},{"key":"pone.0328559.ref007","article-title":"Integrating natural products with modern medicine in the treatment of gouty arthritis: a review","author":"S-S-A Mageed","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"6887","key":"pone.0328559.ref008","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"A Enomoto","year":"2002","journal-title":"Nature"},{"issue":"2","key":"pone.0328559.ref009","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41440-024-02031-9","article-title":"Current updates and future perspectives in uric acid research, 2024","volume":"48","author":"M Kuwabara","year":"2025","journal-title":"Hypertens Res"},{"issue":"11","key":"pone.0328559.ref010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543776.2019.1676727","article-title":"Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019)","volume":"29","author":"Y Dong","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"pone.0328559.ref011","doi-asserted-by":"crossref","first-page":"1428558","DOI":"10.3389\/fphar.2024.1428558","article-title":"Research progress of treating hyperuricemia in rats and mice with traditional Chinese medicine","volume":"15","author":"H Bai","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"pone.0328559.ref012","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1039\/D2RA07193B","article-title":"Virtual screening and activity evaluation of human uric acid transporter 1 (hURAT1) inhibitors","volume":"13","author":"Y Yang","year":"2023","journal-title":"RSC Adv"},{"issue":"3","key":"pone.0328559.ref013","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1021\/jacsau.4c01188","article-title":"Structural Basis for Inhibition of Urate Reabsorption in URAT1","volume":"5","author":"J Fan","year":"2025","journal-title":"JACS Au"},{"key":"pone.0328559.ref014","doi-asserted-by":"crossref","first-page":"101411","DOI":"10.1016\/j.molmet.2021.101411","article-title":"URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice","volume":"55","author":"Y Tanaka","year":"2022","journal-title":"Mol Metab"},{"issue":"24","key":"pone.0328559.ref015","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.3390\/foods12244465","article-title":"Understanding Hyperuricemia: Pathogenesis, Potential Therapeutic Role of Bioactive Peptides, and Assessing Bioactive Peptide Advantages and Challenges","volume":"12","author":"Y Chen","year":"2023","journal-title":"Foods"},{"key":"pone.0328559.ref016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.chroma.2014.03.065","article-title":"High-performance liquid chromatography coupled with post-column dual-bioactivity assay for simultaneous screening of xanthine oxidase inhibitors and free radical scavengers from complex mixture","volume":"1345","author":"D-Q Li","year":"2014","journal-title":"J Chromatogr A"},{"issue":"4","key":"pone.0328559.ref017","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jssc.201301207","article-title":"Screening of xanthine oxidase inhibitors in complex mixtures using online HPLC coupled with postcolumn fluorescence-based biochemical detection","volume":"37","author":"D Li","year":"2014","journal-title":"J Sep Sci"},{"issue":"11","key":"pone.0328559.ref018","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1039\/D3MD00316G","article-title":"Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials","volume":"14","author":"A Singh","year":"2023","journal-title":"RSC Med Chem"},{"key":"pone.0328559.ref019","article-title":"What Is Allopurinol Failure and What Should We Do About It?","author":"L-K Stamp","year":"2024","journal-title":"J Rheumatol"},{"key":"pone.0328559.ref020","doi-asserted-by":"crossref","first-page":"667753","DOI":"10.3389\/fphar.2021.667753","article-title":"Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia","volume":"12","author":"H-L Sun","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"pone.0328559.ref021","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17425255.2023.2287477","article-title":"Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout","volume":"19","author":"Z Hou","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"pone.0328559.ref022","doi-asserted-by":"crossref","first-page":"174291","DOI":"10.1016\/j.ejphar.2021.174291","article-title":"A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications","volume":"907","author":"D Song","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"pone.0328559.ref023","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/13543776.2016.1213243","article-title":"Urate transporter URAT1 inhibitors: a patent review (2012 - 2015)","volume":"26","author":"Y Pan","year":"2016","journal-title":"Expert Opin Ther Pat"},{"issue":"8","key":"pone.0328559.ref024","doi-asserted-by":"crossref","first-page":"114628","DOI":"10.1016\/j.celrep.2024.114628","article-title":"Structural basis for the transport and substrate selection of human urate transporter 1","volume":"43","author":"J He","year":"2024","journal-title":"Cell Rep"},{"issue":"6","key":"pone.0328559.ref025","doi-asserted-by":"crossref","first-page":"102093","DOI":"10.1016\/j.jsps.2024.102093","article-title":"In vitro antimicrobial, anticancer evaluation, and in silico studies of mannopyranoside analogs against bacterial and fungal proteins: Acylation leads to improved antimicrobial activity","volume":"32","author":"M-A Hossain","year":"2024","journal-title":"Saudi Pharm J"},{"issue":"12","key":"pone.0328559.ref026","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/15257770.2024.2333495","article-title":"Synthesis, antimicrobial, and in silico studies of C5\u2019-O-substituted cytidine derivatives: cinnamoylation leads to improvement of antimicrobial activity","volume":"43","author":"T-S Bhuiyan","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"3","key":"pone.0328559.ref027","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/st9.0000000000000038","article-title":"Mechanism of Sishen Pills-Tongxie Yaofang in the treatment of ulcerative colitis based on network pharmacology and experimental verification","volume":"2","author":"H Liu","year":"2024","journal-title":"Sci Tradit Chin Med"},{"issue":"10","key":"pone.0328559.ref028","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1039\/D4FO05274A","article-title":"Identification, saltiness-enhancing effect, and antioxidant properties of novel saltiness-enhancing peptides from peanut protein","volume":"16","author":"P Wang","year":"2025","journal-title":"Food Funct"},{"issue":"2","key":"pone.0328559.ref029","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"O Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"3","key":"pone.0328559.ref030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.37358\/RC.21.3.8446","article-title":"Thermochemical, PASS, Molecular Docking, Drug-Likeness and In Silico ADMET Prediction of Cytidine Derivatives against HIV-1 Reverse Transcriptase","volume":"72","author":"S-M-A Kawsar","year":"2021","journal-title":"Rev Chim"},{"key":"pone.0328559.ref031","doi-asserted-by":"crossref","first-page":"100700","DOI":"10.1016\/j.chphi.2024.100700","article-title":"Acylated glucopyranosides: FTIR, NMR, FMO, MEP, molecular docking, dynamics simulation, ADMET and antimicrobial activity against bacterial and fungal pathogens","volume":"9","author":"N Akter","year":"2024","journal-title":"Chemical Physics Impact"},{"issue":"5","key":"pone.0328559.ref032","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-connectivity fingerprints","volume":"50","author":"D Rogers","year":"2010","journal-title":"J Chem Inf Model"},{"issue":"4","key":"pone.0328559.ref033","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/ci9803381","article-title":"Unsupervised Data Base Clustering Based on Daylight\u2019s Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets","volume":"39","author":"D Butina","year":"1999","journal-title":"J Chem Inf Comput Sci"},{"issue":"3","key":"pone.0328559.ref034","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/biom13030498","article-title":"On the Best Way to Cluster NCI-60 Molecules","volume":"13","author":"S Hern\u00e1ndez-Hern\u00e1ndez","year":"2023","journal-title":"Biomolecules"},{"key":"pone.0328559.ref035","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/DDDT.S97959","article-title":"Guideline development for the management of gout: role of combination therapy with a focus on lesinurad","volume":"11","author":"G Jones","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"pone.0328559.ref036","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ddr.21699","article-title":"The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPAR\u03b3 thereby reducing caspase-1 activity","volume":"81","author":"G Wang","year":"2020","journal-title":"Drug Dev Res"},{"issue":"6","key":"pone.0328559.ref037","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials","volume":"29","author":"D Fitz-Patrick","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"2","key":"pone.0328559.ref038","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2478\/jtim-2022-0031","article-title":"Prevalence and Risk Factors of Hyperuricemia and Gout: A Cross-sectional Survey from 31 Provinces in Mainland China","volume":"10","author":"J Song","year":"2022","journal-title":"J Transl Int Med"},{"issue":"06","key":"pone.0328559.ref039","first-page":"461","article-title":"China multi-disciplinary expert consensus on diagnosis and treatment of hyperuricemia and related diseases (2023 edition)","volume":"43","author":"N-Y Fang","year":"2023","journal-title":"Chin J Pract Intern Med"},{"key":"pone.0328559.ref040","doi-asserted-by":"crossref","first-page":"111220","DOI":"10.1016\/j.cbi.2024.111220","article-title":"Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production","volume":"403","author":"Y-J Chen","year":"2024","journal-title":"Chem Biol Interact"},{"key":"pone.0328559.ref041","doi-asserted-by":"crossref","first-page":"107381","DOI":"10.1016\/j.bioorg.2024.107381","article-title":"Discovery of digallic acid as XOD\/URAT1 dual target inhibitor for the treatment of hyperuricemia","volume":"147","author":"F Zheng","year":"2024","journal-title":"Bioorg Chem"},{"issue":"16","key":"pone.0328559.ref042","doi-asserted-by":"crossref","first-page":"14668","DOI":"10.1021\/acs.jmedchem.4c01480","article-title":"Discovery of a Potent and Orally Bioavailable Xanthine Oxidase\/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout","volume":"67","author":"X Yang","year":"2024","journal-title":"J Med Chem"},{"issue":"7","key":"pone.0328559.ref043","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1080\/07391102.2022.2037463","article-title":"In silico molecular docking study of Andrographis paniculata phytochemicals against TNF-\u03b1 as a potent anti-rheumatoid drug","volume":"41","author":"S-P Tarachand","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"1","key":"pone.0328559.ref044","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/st9.0000000000000020","article-title":"Function and application of Traditional Chinese Medicine Inheritance Calculate System","volume":"2","author":"S Tang","year":"2024","journal-title":"Sci Tradit Chin Med"},{"key":"pone.0328559.ref045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/bs.pmch.2021.01.004","article-title":"Use of molecular docking computational tools in drug discovery","volume":"60","author":"F Stanzione","year":"2021","journal-title":"Prog Med Chem"},{"issue":"5","key":"pone.0328559.ref046","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"S Forli","year":"2016","journal-title":"Nat Protoc"},{"issue":"1","key":"pone.0328559.ref047","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1038\/s41467-022-33981-8","article-title":"Chemical space docking enables large-scale structure-based virtual screening to discover ROCK1 kinase inhibitors","volume":"13","author":"P Beroza","year":"2022","journal-title":"Nat Commun"},{"key":"pone.0328559.ref048","doi-asserted-by":"crossref","first-page":"463816","DOI":"10.1016\/j.chroma.2023.463816","article-title":"Chemical profile of anti-epidemic sachet based on multiple sample preparation coupled with gas chromatography-mass spectrometry analysis combined with an embedded peaks resolution method and their action mechanisms","volume":"1691","author":"L Hong","year":"2023","journal-title":"J Chromatogr A"},{"issue":"2","key":"pone.0328559.ref049","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/st9.0000000000000033","article-title":"Anti-acute gastric ulcer resistance of Aurantii Fructus Immaturus juice processing Atractylodis Macrocephalae Rhizoma by regulating PTGS2, MAPK1, and KDR targets based on metabolomics and integrated network pharmacology analysis","volume":"2","author":"W Xu","year":"2024","journal-title":"Sci Tradit Chin Med"},{"issue":"7","key":"pone.0328559.ref050","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"L-G Ferreira","year":"2015","journal-title":"Molecules"},{"key":"pone.0328559.ref051","doi-asserted-by":"crossref","first-page":"105452","DOI":"10.1016\/j.compbiomed.2022.105452","article-title":"Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19","volume":"145","author":"\u015e Adem","year":"2022","journal-title":"Comput Biol Med"},{"issue":"2","key":"pone.0328559.ref052","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/jmbi.2001.4956","article-title":"Tyrosine hydrogen bonds make a large contribution to protein stability","volume":"312","author":"C-N Pace","year":"2001","journal-title":"J Mol Biol"},{"issue":"7743","key":"pone.0328559.ref053","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","article-title":"Ultra-large library docking for discovering new chemotypes","volume":"566","author":"J Lyu","year":"2019","journal-title":"Nature"},{"issue":"23","key":"pone.0328559.ref054","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1016\/j.bmcl.2017.09.041","article-title":"Improvement in aqueous solubility achieved via small molecular changes","volume":"27","author":"M-A Walker","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"issue":"13","key":"pone.0328559.ref055","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.12998\/wjcc.v7.i13.1717","article-title":"Liver failure associated with benzbromarone: A case report and review of the literature","volume":"7","author":"M-Y Zhang","year":"2019","journal-title":"World J Clin Cases"},{"key":"pone.0328559.ref056","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2147\/DDDT.S140658","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects","volume":"11","author":"Z Shen","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"pone.0328559.ref057","doi-asserted-by":"crossref","first-page":"5738900","DOI":"10.1155\/2021\/5738900","article-title":"Recent Updates of Natural and Synthetic URAT1 Inhibitors and Novel Screening Methods","volume":"2021","author":"Y Chen","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"issue":"7","key":"pone.0328559.ref058","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5414\/CP203425","article-title":"Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials","volume":"57","author":"G-G Song","year":"2019","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:50:24Z","timestamp":1755107424000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328559"}},"subtitle":[],"editor":[{"given":"Gayathiri","family":"Ekambaram","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328559","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}